PL2608809T3 - Przeciwciała dla metaloproteinazy 9 macierzy - Google Patents
Przeciwciała dla metaloproteinazy 9 macierzyInfo
- Publication number
- PL2608809T3 PL2608809T3 PL11820759T PL11820759T PL2608809T3 PL 2608809 T3 PL2608809 T3 PL 2608809T3 PL 11820759 T PL11820759 T PL 11820759T PL 11820759 T PL11820759 T PL 11820759T PL 2608809 T3 PL2608809 T3 PL 2608809T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- matrix metalloproteinase
- metalloproteinase
- matrix
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37788610P | 2010-08-27 | 2010-08-27 | |
| PCT/US2011/049448 WO2012027721A2 (en) | 2010-08-27 | 2011-08-26 | Antibodies to matrix metalloproteinase 9 |
| EP11820759.6A EP2608809B1 (en) | 2010-08-27 | 2011-08-26 | Antibodies to matrix metalloproteinase 9 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2608809T3 true PL2608809T3 (pl) | 2019-10-31 |
Family
ID=45724100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11820759T PL2608809T3 (pl) | 2010-08-27 | 2011-08-26 | Przeciwciała dla metaloproteinazy 9 macierzy |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US8377443B2 (pl) |
| EP (1) | EP2608809B1 (pl) |
| JP (3) | JP5878538B2 (pl) |
| KR (4) | KR101518144B1 (pl) |
| CN (2) | CN104530238B (pl) |
| AP (2) | AP3948A (pl) |
| AU (1) | AU2011293125B2 (pl) |
| BR (1) | BR112013004579B1 (pl) |
| CA (1) | CA2808418C (pl) |
| CL (1) | CL2013000535A1 (pl) |
| CO (1) | CO6680656A2 (pl) |
| CR (1) | CR20130132A (pl) |
| EA (1) | EA031729B1 (pl) |
| EC (1) | ECSP13012525A (pl) |
| ES (1) | ES2739505T3 (pl) |
| HK (1) | HK1208688A1 (pl) |
| IL (2) | IL224614A (pl) |
| MA (1) | MA34527B1 (pl) |
| MX (1) | MX342413B (pl) |
| NZ (2) | NZ606880A (pl) |
| PE (1) | PE20131376A1 (pl) |
| PH (1) | PH12016501691A1 (pl) |
| PL (1) | PL2608809T3 (pl) |
| PT (1) | PT2608809T (pl) |
| SG (2) | SG10201506703VA (pl) |
| SI (1) | SI2608809T1 (pl) |
| TR (1) | TR201910348T4 (pl) |
| UA (1) | UA109908C2 (pl) |
| WO (1) | WO2012027721A2 (pl) |
| ZA (2) | ZA201301338B (pl) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101518144B1 (ko) | 2010-08-27 | 2015-05-28 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 ９에 대한 항체 |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| WO2013130078A1 (en) | 2012-02-29 | 2013-09-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
| JP6144286B2 (ja) * | 2012-02-29 | 2017-06-07 | ギリアード バイオロジックス， インコーポレイテッド | マトリックスメタロプロテイナーゼ９に対する抗体 |
| EP3290047A1 (en) * | 2013-04-05 | 2018-03-07 | Claudia Zylberberg | Matrix metalloproteinases and uses thereof |
| US20150148345A1 (en) | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| WO2015109286A1 (en) | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Therapies for treating cancers |
| EP2985296A1 (en) | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
| EP2985295A1 (en) * | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| MA39601A (fr) | 2015-03-04 | 2016-11-30 | Gilead Sciences Inc | Composés 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du récepteur de type toll |
| CN105037553B (zh) * | 2015-08-20 | 2018-04-17 | 内蒙古蒙元生物基因科技有限公司 | 一种能够检测癌症的免疫球蛋白 |
| JP2018530550A (ja) | 2015-10-01 | 2018-10-18 | ギリアド サイエンシズ， インコーポレイテッド | 癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ |
| WO2017106566A1 (en) * | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
| EA201891024A1 (ru) | 2015-12-17 | 2018-12-28 | Джилид Сайэнс, Инк. | Соединения-ингибиторы tank-связывающей киназы |
| WO2017152062A1 (en) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| EP3440113A1 (en) | 2016-04-08 | 2019-02-13 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| BR112018075737A2 (pt) | 2016-06-13 | 2019-03-26 | I-Mab | anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra. |
| MA45848A (fr) | 2016-08-04 | 2019-06-12 | Gilead Sciences Inc | Cobicistat destiné à être utilisé dans des traitements du cancer |
| SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| WO2018097977A1 (en) | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| US10894837B2 (en) | 2016-12-16 | 2021-01-19 | Université De Bordeaux | MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder |
| EP3383916B1 (en) | 2017-01-24 | 2022-02-23 | I-Mab Biopharma US Limited | Anti-cd73 antibodies and uses thereof |
| WO2018156895A1 (en) | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP3585789A1 (en) | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| US10941178B2 (en) | 2017-03-17 | 2021-03-09 | Gilead Sciences, Inc. | Method of purifying an antibody |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2019017338A1 (ja) | 2017-07-18 | 2019-01-24 | 第一三共株式会社 | 活性型ｍｍｐ－９結合ペプチド |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN118084940A (zh) | 2018-02-13 | 2024-05-28 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| EP3781556A1 (en) | 2018-04-19 | 2021-02-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| WO2019217780A1 (en) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| PL3793565T3 (pl) | 2018-05-14 | 2022-05-02 | Gilead Sciences, Inc. | Inhibitory MCL-1 |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
| JP7273172B2 (ja) | 2018-10-31 | 2023-05-12 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物 |
| KR20210137518A (ko) | 2019-03-07 | 2021-11-17 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ２’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
| US20210147568A1 (en) | 2019-10-31 | 2021-05-20 | Forty Seven, Inc. | Anti-cd47 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| US11845723B2 (en) | 2019-12-24 | 2023-12-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| AU2021219668A1 (en) | 2020-02-14 | 2022-08-25 | Gilead Sciences, Inc. | Antibodies and fusion proteins that bind to CCR8 and uses thereof |
| BR112022020769A2 (pt) | 2020-05-01 | 2022-12-20 | Gilead Sciences Inc | Compostos de 2,4-dioxopirimidina de inibição de cd73 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11999733B2 (en) | 2021-06-23 | 2024-06-04 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| JP2024522594A (ja) | 2021-06-23 | 2024-06-21 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS |
| WO2023278491A1 (en) * | 2021-06-28 | 2023-01-05 | Releviate, Llc | Mmp-9 antibodies and uses thereof |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| KR20240125012A (ko) | 2021-12-22 | 2024-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| IL316058A (en) | 2022-04-21 | 2024-11-01 | Gilead Sciences Inc | Compounds modulate KRAS G12D |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE69412466T2 (de) | 1993-11-30 | 1999-04-29 | Fuji Yakuhin Kogyo K.K., Takaoka, Toyama | Neue metalloprotease und kodierende dna dafür |
| US5612030A (en) | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| ATE435031T1 (de) | 1999-07-13 | 2009-07-15 | Univ Southern California | Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine |
| US7101975B1 (en) | 1999-07-13 | 2006-09-05 | University Of Southern California | Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins |
| WO2002066057A2 (en) | 2001-02-23 | 2002-08-29 | Biophage Inc. | Methods and compositions for preventing and treating neutrophil-mediated diseases |
| SE0102298D0 (sv) | 2001-06-27 | 2001-06-27 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
| US20030139332A1 (en) | 2001-07-09 | 2003-07-24 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
| WO2003044058A2 (en) | 2001-11-23 | 2003-05-30 | Universite Catholique De Louvain | Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis |
| JP4601426B2 (ja) | 2002-09-06 | 2010-12-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体成分ｃ５に対する抗体を使用する喘息の処置の方法 |
| WO2004076614A2 (de) | 2003-02-27 | 2004-09-10 | Bernd Hinzmann | Humane nukleinsäuresequenzen aus prostatakarzinomen |
| EP1610678B1 (en) * | 2003-04-04 | 2011-07-27 | Yeda Research And Development Co., Ltd. | Antibodies for inhibiting the activity of mmp-2 and mmp-9 |
| WO2006037513A1 (en) | 2004-10-09 | 2006-04-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9) |
| EP1904846A4 (en) | 2005-06-29 | 2009-03-18 | Rules Based Medicine Inc | METHOD AND KITS FOR THE DIAGNOSIS OF ACUTE CORONARY SYNDROME |
| CA2631327C (en) | 2005-12-02 | 2015-10-13 | Genentech, Inc. | Her2 binding polypeptides and uses thereof |
| WO2007144781A2 (en) | 2006-04-21 | 2007-12-21 | Diagnotech Pty. Ltd. | Diagnostic methods and kits utilizing antibodies for metalloproteases |
| WO2008088864A2 (en) | 2007-01-18 | 2008-07-24 | The Trustess Of Columbia University In The City Of New York | Matrix metalloproteinase-9-related methods |
| WO2008102359A1 (en) * | 2007-02-23 | 2008-08-28 | Yeda Research And Development Co. Ltd. | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| PE20090765A1 (es) | 2007-06-08 | 2009-07-10 | Irm Llc | Metodos y composiciones para inducir la apoptosis en celulas cancerosas |
| BRPI0814479A2 (pt) | 2007-08-15 | 2016-07-12 | Yeda Res & Dev | "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica" |
| JP2011506614A (ja) | 2007-12-17 | 2011-03-03 | ダイアックス コーポレーション | Ｍｍｐ−１４結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法 |
| AU2009221916A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| CA2717576A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 binding proteins |
| US20110262396A1 (en) | 2008-10-22 | 2011-10-27 | Dyax Corp. | Combination treatments comprising protease binding proteins for inflammatory disorders |
| US20110286916A1 (en) | 2008-11-20 | 2011-11-24 | Jose Miguel Aste-Amezaga | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
| CA2787311C (en) | 2010-01-27 | 2017-08-15 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
| US20110261695A1 (en) * | 2010-04-23 | 2011-10-27 | Xiaoming Zhao | System and method for network congestion control |
| KR101518144B1 (ko) | 2010-08-27 | 2015-05-28 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 ９에 대한 항체 |
| WO2013130078A1 (en) | 2012-02-29 | 2013-09-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
| JP6144286B2 (ja) | 2012-02-29 | 2017-06-07 | ギリアード バイオロジックス， インコーポレイテッド | マトリックスメタロプロテイナーゼ９に対する抗体 |
-
2011
- 2011-08-26 KR KR1020137007599A patent/KR101518144B1/ko active IP Right Grant
- 2011-08-26 MX MX2013002323A patent/MX342413B/es active IP Right Grant
- 2011-08-26 KR KR1020177006624A patent/KR101930179B1/ko active IP Right Grant
- 2011-08-26 NZ NZ606880A patent/NZ606880A/en not_active IP Right Cessation
- 2011-08-26 AU AU2011293125A patent/AU2011293125B2/en active Active
- 2011-08-26 EA EA201390146A patent/EA031729B1/ru not_active IP Right Cessation
- 2011-08-26 BR BR112013004579-5A patent/BR112013004579B1/pt not_active IP Right Cessation
- 2011-08-26 SI SI201131732T patent/SI2608809T1/sl unknown
- 2011-08-26 CA CA2808418A patent/CA2808418C/en active Active
- 2011-08-26 PE PE2013000344A patent/PE20131376A1/es active IP Right Grant
- 2011-08-26 UA UAA201302088A patent/UA109908C2/uk unknown
- 2011-08-26 WO PCT/US2011/049448 patent/WO2012027721A2/en active Application Filing
- 2011-08-26 SG SG10201506703VA patent/SG10201506703VA/en unknown
- 2011-08-26 AP AP2013006743A patent/AP3948A/en active
- 2011-08-26 ES ES11820759T patent/ES2739505T3/es active Active
- 2011-08-26 JP JP2013526186A patent/JP5878538B2/ja active Active
- 2011-08-26 SG SG2013011341A patent/SG188224A1/en unknown
- 2011-08-26 CN CN201410816632.5A patent/CN104530238B/zh active Active
- 2011-08-26 CN CN201180041422.8A patent/CN103140240B/zh active Active
- 2011-08-26 EP EP11820759.6A patent/EP2608809B1/en active Active
- 2011-08-26 KR KR1020147035325A patent/KR101827048B1/ko active IP Right Grant
- 2011-08-26 TR TR2019/10348T patent/TR201910348T4/tr unknown
- 2011-08-26 AP AP2016009448A patent/AP2016009448A0/en unknown
- 2011-08-26 MA MA35741A patent/MA34527B1/fr unknown
- 2011-08-26 NZ NZ701444A patent/NZ701444A/en not_active IP Right Cessation
- 2011-08-26 PL PL11820759T patent/PL2608809T3/pl unknown
- 2011-08-26 PT PT11820759T patent/PT2608809T/pt unknown
- 2011-08-26 US US13/219,523 patent/US8377443B2/en active Active
- 2011-08-26 KR KR1020187002896A patent/KR101881724B1/ko active IP Right Grant
-
2012
- 2012-09-14 US US13/619,318 patent/US8501916B2/en active Active
-
2013
- 2013-02-07 IL IL224614A patent/IL224614A/en active IP Right Grant
- 2013-02-20 ZA ZA2013/01338A patent/ZA201301338B/en unknown
- 2013-02-22 CO CO13036730A patent/CO6680656A2/es unknown
- 2013-02-25 CL CL2013000535A patent/CL2013000535A1/es unknown
- 2013-03-21 CR CR20130132A patent/CR20130132A/es unknown
- 2013-03-25 EC ECSP13012525 patent/ECSP13012525A/es unknown
- 2013-07-03 US US13/935,352 patent/US9260532B2/en active Active
- 2013-07-03 US US13/935,370 patent/US9120863B2/en active Active
-
2015
- 2015-08-28 US US14/839,503 patent/US20160159923A1/en not_active Abandoned
- 2015-09-24 HK HK15109390.0A patent/HK1208688A1/xx unknown
- 2015-09-25 ZA ZA2015/07081A patent/ZA201507081B/en unknown
- 2015-10-23 JP JP2015208653A patent/JP6198797B2/ja active Active
-
2016
- 2016-01-11 US US14/992,678 patent/US20160122437A1/en not_active Abandoned
- 2016-08-25 PH PH12016501691A patent/PH12016501691A1/en unknown
-
2017
- 2017-08-22 JP JP2017159712A patent/JP6435381B2/ja active Active
- 2017-09-05 US US15/695,765 patent/US20180086845A1/en not_active Abandoned
- 2017-10-29 IL IL255300A patent/IL255300A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255300A0 (en) | Antibodies to matrix metalloproteinase 9 (mmp9) | |
| HK1248246A1 (zh) | 抗基質金屬蛋白酶9的抗體 | |
| ZA201406319B (en) | Antibodies to matrix metalloproteinase 9 | |
| IL228001A0 (en) | Antibodies to 70cd | |
| HK1217711A1 (zh) | 特異於鈣粘素- 的抗體 | |
| ZA201302983B (en) | Antibodies to notum pectinacetylesterase | |
| GB2476329B (en) | Improved access to structures | |
| SG10201700568RA (en) | Antibodies to matrix metalloproteinase 9 | |
| GB201013445D0 (en) | Made to go! | |
| GB201001372D0 (en) | Brickies aid to pillars | |
| GB201000585D0 (en) | Brickers aid to pillars |